cell lung cancer should begin chemotherapy within 4 weeks. Radiotherapy departments may cause delays in radical field planning because often there is a failure to prioritize lung cancer. However, all this is achievable.
Will the changes make any difference? Yes, it will make the patient journey faster and more efficient, although patients may not want to proceed at this speed and may lose contact with their initial physician, risking communication problems, at a time in their lives when huge decisions need to be made. The MDT and the organization around it make it difficult for a patient to drop out or be forgotten. It also provides a conduit for all patients with lung cancer to be presented, preventing other medical groups from hanging onto these cases.
The funding of a national data set for lung cancer (LUCADA) will provide a unique opportunity to follow the standards of lung cancer care in the United Kingdom. More than 800 patients a month are being entered from all over the country and this should now increase as data entry becomes mandatory. However, the most important question is whether this political innovation to improve the patient journey will improve survival for the disease, which is the main objective. Improving the patient journey alone may improve survival for a few patients previously not offered prompt expert exposure who may now undergo an operation, radical radiotherapy, etc. However, the most important determinant of survival is the innate biology of the tumor. Rapidly growing disease is unlikely to be converted from incurable to curable by a few weeks' faster detection, and slowly growing cancers may still be curable if missed for 6 months. With doubling rates of 30 to 120 days, and the average lung cancer presenting at 3 to 4 cm in diameter on a chest radiograph, 35 volume doubling times (3 to 12 years) will have passed before diagnosis, making the weeks saved by the National Cancer Plan irrelevant. Nevertheless, it has introduced an improving system of care, a welcome reorganization of MDT working, an opportunity to improve entry of patients into clinical trials, and a national data set that will become the benchmark for future improvements in care but probably not have much effect on overall cure rates.
